Loading
x
This website uses essential cookies. With your consent, we place Google Analytics cookies for statistics.

Cookie Policy for Slzii.com

This is the Cookie Policy for Slzii.com, accessible from slzii.com

What Are Cookies

As is common practice with almost all professional websites this site uses cookies, which are tiny files that are downloaded to your computer, to improve your experience. This page describes what information they gather, how we use it and why we sometimes need to store these cookies. We will also share how you can prevent these cookies from being stored however this may downgrade or 'break' certain elements of the sites functionality.

How We Use Cookies

We use cookies for a variety of reasons detailed below. Unfortunately in most cases there are no industry standard options for disabling cookies without completely disabling the functionality and features they add to this site. It is recommended that you leave on all cookies if you are not sure whether you need them or not in case they are used to provide a service that you use.

Disabling Cookies

You can prevent the setting of cookies by adjusting the settings on your browser (see your browser Help for how to do this). Be aware that disabling cookies will affect the functionality of this and many other websites that you visit. Disabling cookies will usually result in also disabling certain functionality and features of the this site. Therefore it is recommended that you do not disable cookies. This Cookies Policy was created with the help of the Cookies Policy Generator.

The Cookies We Set

  • Account related cookies

    If you create an account with us then we will use cookies for the management of the signup process and general administration. These cookies will usually be deleted when you log out however in some cases they may remain afterwards to remember your site preferences when logged out.

  • Login related cookies

    We use cookies when you are logged in so that we can remember this fact. This prevents you from having to log in every single time you visit a new page. These cookies are typically removed or cleared when you log out to ensure that you can only access restricted features and areas when logged in.

  • Site preferences cookies

    In order to provide you with a great experience on this site we provide the functionality to set your preferences for how this site runs when you use it. In order to remember your preferences we need to set cookies so that this information can be called whenever you interact with a page is affected by your preferences.

Third Party Cookies

In some special cases we also use cookies provided by trusted third parties. The following section details which third party cookies you might encounter through this site.

  • This site uses Google Analytics which is one of the most widespread and trusted analytics solution on the web for helping us to understand how you use the site and ways that we can improve your experience. These cookies may track things such as how long you spend on the site and the pages that you visit so we can continue to produce engaging content.

    For more information on Google Analytics cookies, see the official Google Analytics page.

  • Third party analytics are used to track and measure usage of this site so that we can continue to produce engaging content. These cookies may track things such as how long you spend on the site or pages you visit which helps us to understand how we can improve the site for you.

  • From time to time we test new features and make subtle changes to the way that the site is delivered. When we are still testing new features these cookies may be used to ensure that you receive a consistent experience whilst on the site whilst ensuring we understand which optimisations our users appreciate the most.

  • We also use social media buttons and/or plugins on this site that allow you to connect with your social network in various ways. For these to work the following social media sites including; {List the social networks whose features you have integrated with your site?:12}, will set cookies through our site which may be used to enhance your profile on their site or contribute to the data they hold for various purposes outlined in their respective privacy policies.

More Information

Hopefully that has clarified things for you and as was previously mentioned if there is something that you aren't sure whether you need or not it's usually safer to leave cookies enabled in case it does interact with one of the features you use on our site.

For more general information on cookies, please read the Cookies Policy article.

However if you are still looking for more information then you can contact us through one of our preferred contact methods:

  • By visiting this link: https://www.slzii.com/contact

Search (News)

晶泰科技参与耀速科技超2亿元A轮融资,AI+器官芯片+自动化构建下一代药物研发基础设施
上海 2026年4月3日 /美通社/ -- 近日,全球领先的 "AI+器官芯片" 驱动的科技平台企业 耀速科技(Xellar Biosystems)宣布完成超 2 亿元人民币 A 轮融资。 本轮融资由国寿股权独家领投,老股东晶泰科技、雅亿资本、君联资本持续加码。本轮资金将重点投入于构建 以人源化模型与机制研究为核心的下一代生物智能基础设施 ,包括拓展器官芯片疾病模型体系,建立可规模化运行的机制研究平台,并持续进行高通量、标准化的真实生物数据采集与积累。在此基础上,公司将加速推进以专有 3D 湿实验数据为核心驱动的 AI 平台建设与合作,融合多模态数据建模、计算机视觉与知识图谱,实现 "数据生成—机制解析—模型训练—实验验证" 的闭环飞轮,逐步构建具备动态表征与预测能力的 "真实世界数据(Real World Data)+虚拟细胞(Virtual Cell)" 为基础的 3D Bio Intelligence 体系,实现对复杂生物过程的数字化重建与机制推演。 耀速科 技由哈佛科学家团队创立,是一家以 器官芯片(Organ-on-a-Chip)为核心,深度融合人工智能、自动化与高通量实验系统的 AI for 3D Biology 平台公司,致力于通过高保真模拟人类生理与疾病状态,重构下一代药物研发新范式。公司平台可在更接近真实人体的条件下,实现标准化、可重复、可量化的数据生成,并通过 AI 模型持续学习与迭代,显著提升药物研发的预测能力与研发效率。 晶泰科技 作为耀速科技的战略投资方, 在 AI+机器人赋能新药研发领域拥有行业领先技术和丰富的成功经验,已与耀速科技在 AI+器官芯片驱动的药物筛选和药效评估领域展开合作并取得初步成果。双方基于各自平台的技术优势,将体外复杂模型与 AI 药物研发技术融合,以更接近真实人体反应的类器官模型和器官芯片等技术,实现更加精确高效的药物表型筛选与关键药效验证, 助力晶泰科技发现、设计、交付更具临床潜力的药物分子 。双方还进一步整合器官芯片技术与机器人自动化实验,开发新一代高通量药物筛选与表型技术,打通智能算法与机器人实验的数据闭环,进一步提高药物发现的效率与成功率 ,广泛赋能新一代创新药研发,为行业创造价值。 目前,耀速科技已与多家全球头部药企、消费健康与美妆集团建立长期合作关系,相关业务在过去一年中保持高速增长。公司在药物安全性评价、疾病模型构建、化合物功效验证等多个关键应用场景实现稳定落地,逐步形成以平台能力、标准体系与数据资产为核心的可持续商业模式。 在监管与国际标准层面,耀速科技近期取得重要进展。公司器官芯片平台从 2023 年开始与 3Rs 组织和 FDA 开展合作,并于今年一月正式被 美国食品药品监督管理局(FDA) 接收进入其 创新科学与技术推进计划(ISTAND,Innovative Science and Technology Approaches for New Drugs)的评审通道,有望成为全球首批获得 FDA 科学认可与资格认定的药物开发工具(Drug Development Tool,DDT)。在该路径下,相关技术一旦完成监管层面的验证,将可被药企直接作为合规工具用于新药研发,并进入 IND 申报及后续开发流程, 显著降低药物研发中的不确定性与重复实验成本。这一进展标志着耀速科技的平台能力正从研发工具层面,向监管认可的基础设施级能力加速演进。 本轮融资完成后,耀速科技将持续加大在人工智能与计算团队建设上的投入,推动多模态生物数据建模、预测模型及大模型能力的协同发展。同时,公司将与晶泰科技深度合作,推进自动化实验平台的工业化落地,实现器官芯片实验执行与数据采集的高度标准化与规模化,并系统性构建器官芯片与疾病机制、药效毒性及生物通路关联的知识图谱,为下一阶段更大规模的智能决策与管线共建奠定数据基础。 晶泰科技董事局主席温书豪表示: 作为老股东,我们见证了耀速团队从技术理念到平台落地,再到商业验证的快速跨越。近年来,FDA 对器官芯片的重视与认可不断提升,这一技术有望成为主流研发方式之一。而当器官芯片与 AI、自动化深度融合,将真正构筑起下一代药物研发的基础系统。我们持续加码,正是基于对其平台战略价值与商业化执行力的高度信心,也期待双方在智能研发生态中实现更深层次的协同。 耀速科技创始人兼 CEO 谢鑫表示: 衷心感谢新老股东对耀速科技的认可与大力支持。本轮融资是对我们 "AI for 3D Biology" 平台战略和团队执行力的重要背书。融资完成后,我们将全力投入到 AI 计算团队扩建、自动化体系的规模化落地以及多模态知识图谱的构建中,持续夯实我们的技术壁垒。与中美药监机构同步的合作进展,标志着我们的平台正迈向监管认可的行业基础设施。我们将携手合作伙伴,加速推进 "3D Bio Intelligence" 在新药研发各环节的深入应用,切实降低研发成本与风险,为全球患者带来更多突破性疗法。 国寿股权公司表示: 我们非常看好耀速科技在 "AI+器官芯片" 领域的创新布局与领先优势。其技术平台不仅具备高度工程化和规模化的潜力,更在监管认可路径上取得了实质性突破。我们期待陪伴耀速成长为全球药物研发新范式的关键推动者,助力中国生物科技源头创新走向世界。 君联资本表示: 耀速科技具备全球顶尖的器官芯片与 AI 、高通量湿实验结合的技术平台。团队兼具前沿科学洞察、工程化能力和商业落地韧性,在器官芯片产品、国际科学监管机构合作和行业标准推动、头部药企合作等方面不断突破。君联资本从天使轮以来多轮持续追加投资,看好公司平台能力和商业价值的加速释放。 雅亿资本创始合伙人刘翀表示: 耀速科技将高仿真器官芯片的自动化实验体系与多模态 AI 深度融合,打通了 "实验—模型—数据—预测" 的全链路闭环,推动药物研发向数据与智能驱动的范式升级。公司凭借扎实的平台能力,已获得多家全球头部企业的认可与合作,并在 FDA 监管路径上取得关键进展,充分验证了其技术的科学性、稳定性与应用价值。我们非常高兴持续支持耀速科技,期待其将这一平台打造为全球药物研发体系中标准化、可信赖的关键基础设施。 关于耀速科技 耀速科技 2021 年底创立于美国波士顿,是全球首家利用器官芯片结合高内涵三维(3D)细胞成像,计算机视觉(CV)和人工智能(AI)进行药物发现和精准医学研究的 "3D Bio Intelligence" 生物科技初创公司。耀速创始团队成员多来自于知名跨国生物医药企业及哈佛大学,麻省理工学院等顶尖科研院所,具有丰富的工业界医药产品开发和前沿生物与 AI 技术研发经验。耀速正作为唯一一家中国公司和中美药监机构联合制定器官芯片全球首个行业标准。耀速科技与多家生物制药公司和科研院所开展了战略与科研合作。 关于晶泰科技 晶泰科技("XtalPi Holdings Limited",股份简称:晶泰控股,XTALPI,股票代码:2228.HK)由三位麻省理工学院的物理学家于 2015 年创立,是一个基于量子物理、以人工智能赋能和机器人驱动的创新型研发平台。公司采用基于量子物理的第一性原理计算、人工智能、高性能云计算以及可扩展及标准化的机器人自动化相结合的方式,为制药及材料科学(包括农业技术、能源及新型化学品以及化妆品)等产业的全球和国内公司提供药物及材料科学研发解决方案及服务。
2026-04-03 00:37:00

0.039231061935425


News
News

Latest News and Headlines
上海 2026年4月3日 /美通社/ -- 近日,全球领先的 AI+器官芯片 驱动的科技平台企业 耀速科技(Xellar Biosystems)宣布完成超 2 亿元人民币 A 轮融资。 本轮融资由国寿股权独家领投,老股东晶泰科技、雅亿资本、君联资本持续加码。本轮资金将重点投入...
News